Pathios Therapeutics

Investors · 1

CA

Canaan PartnersStamford · $500K – $20M

PA

Pathos22 shared keywordsPathos applies AI, biological modeling, and a large collection of multimodal oncology patient data to develop cancer drugs and accelerate clinical development. It operates the PathOS platform with engines for asset selection, clinical trial execution, and an oncology foundation model.

BI

Bioworld15 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

AR

Artios Pharma14 shared keywordsArtios develops DNA Damage Response (DDR)-based therapeutics for hard-to-treat solid tumors, including small-molecule inhibitors targeting ATR (alnodesertib) and DNA polymerase theta (ART6043). The company operates a proprietary DDR drug-development platform called DcoDeR and advances a pipeline of oncology product candidates through clinical trials.

Companies competing with Pathios Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Registered name

PATHIOS THERAPEUTICS LIMITED

Company number

10641754

Status

Active

Company type

Private limited company

Incorporated

27 Feb 2017

Registered office

99 Park Drive, Milton, Abingdon, OX14 4RY

Nature of business (SIC)

72110 — Research and experimental development on biotechnology

Accounts

last made up to 31 Dec 2025 · next due 30 Sept 2027

Confirmation statement

last made up to 26 Feb 2026 · next due 12 Mar 2027

Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.